Aventis Pharma S.a.

Sanofi

Sanofi-a Ventis Deutschland Gmbh

Anke Steinmetz

Hans Matter

David William Will

Ingrid Sassoon

Karl Schoenafinger

Swen Hoelder

Christine Delaisi

Gunter Muller

Cecile Combeau

Ercole Rao

Christian Lange

Vincent Mikol

Martin Bossart

Carsten Corvey

Nicolas Baurin

Danxi Li

Didier Benard

Cécile Combeau

Chirstian Biel

Baptiste Ronan

Eric Bacque

Jidong Zhang

Christian Beil

Vincent Leroy

Yannick Benedetti

Karl Schönafinger

Thomas Rooney

Franck Halley

Bernard Baudoin

Gilles Tiraboschi

Jean-Philippe Letallec

Odile Angouillant-Boniface

Emmanuel Conseiller

Günter Müller

François Clerc

Daniel Bezard

Stéphanie Deprets

Thorsten Naumann

Swen Hölder

Günther Müller

Dominique Le Suisse

Rao Ercole

The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.

Dual variable region antibody-like binding proteins having cross-over binding region orientation

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

The invention especially relates to novel chemical compounds, especially novel benzothiazole derivatives, to compositions containing said compounds, and to the use thereof as medicaments.

Benzothiazoles and the use thereof as medicaments

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein 

Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them

Growing community of inventors

Vitry sur Seine, France

Anke Steinmetz